Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $108.65 USD
Change Today +1.11 / 1.03%
Volume 5.6M
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CELG) Snapshot

Open
$108.49
Previous Close
$107.54
Day High
$108.99
Day Low
$106.45
52 Week High
03/20/15 - $129.06
52 Week Low
05/9/14 - $71.32
Market Cap
86.2B
Average Volume 10 Days
6.5M
EPS TTM
$3.08
Shares Outstanding
793.1M
EX-Date
--
P/E TM
35.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP (CELG)

celgene corp (CELG) Related Businessweek News

View More BusinessWeek News

celgene corp (CELG) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp (CELG) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.4M
President and Chief Operating Officer
Total Annual Compensation: $767.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $400.0K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $666.5K
President of Global Hematology and Oncology
Total Annual Compensation: $803.3K
Compensation as of Fiscal Year 2014.

celgene corp (CELG) Key Developments

Celgene Corporation Announces Results from A Pre-Specified Secondary Endpoint Analysis of MDS-005

Celgene Corporation announced results from a pre-specified secondary endpoint analysis of MDS-005, a multicenter, randomized, placebo controlled phase III study of REVLMID (lenalidomide) compared with placebo in patients with non-del-5q myelodysplastic syndromes (MDS). The analysis was presented during the 13th International Symposium on Myelodysplastic Syndromes. Results from MDS-005 were originally presented at the 2014 American Society of Hematology annual meeting and reported that significantly more patients treated with lenalidomide achieved red-blood-cell-transfusion independence (RBC-TI) of at least 56 days compared with placebo (26.9%, [43/160 patients] vs. 2.5%, [2/79 patients]. In the United States, REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma. REVLIMID is also approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand. REVLIMID is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities and in Europe for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. In addition, REVLIMID is approved in the United States for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. U.S. Regulatory Information for REVLIMID REVLIMID (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of patients with multiple myeloma (MM) REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1 "risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib REVLIMID is not indicated and not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Celgene Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year 2015

Celgene Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net product sales of $2,055.2 million against $1,707.5 million a year ago. Operating income was $859.0 million against $361.8 million a year ago. Income before income taxes was $827.1 million against $332.3 million a year ago. Total revenue increased 20% to $2,081 million compared to $1,730 million in the first quarter of 2014. Adjusted net income increased 26% to $891 million compared to $705 million in the first quarter of 2014. Adjusted diluted earnings per share increased 29% to $1.07 from $0.83, on a stock split-adjusted basis. Net income was $719 million or $0.86 per diluted share. For the first quarter of 2014, net income was $280 million or $0.33 per diluted share, on a stock split-adjusted basis. The company is reaffirming 2015 earnings guidance. The company announced that total net product sales are expected to be $9,000 million to $9,500 million, adjusted operating margin is expected to be approximately 52%, GAAP operating margin is expected to be approximately 36.4%, adjusted diluted EPS is expected to be in the range of $4.60 to $4.75 and the firm has lowered its GAAP EPS guidance to $2.97 to $3.19 from $3.68 and $3.92. The company expects GAAP net income between $2,468.2 million to $2,651.5 million, adjusted net income between $3,818.0 million to $3,942.5 million and amortization of acquired intangible assets of $254.6 million.

Acceleron Pharma, Inc. and Celgene Corporation Plan to Initiate a Phase 3 Program with Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia by Year-End 2015

Acceleron Pharma, Inc. announced that Acceleron and its collaboration partner, Celgene Corporation, plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015. The companies will continue to develop sotatercept for patients with chronic kidney disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $108.65 USD +1.11

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $383.56 USD -2.24
Bristol-Myers Squibb Co $64.67 USD -0.36
Eli Lilly & Co $72.05 USD +0.14
Mylan NV $71.05 USD -1.84
Shire PLC 5,205 GBp 0.00
View Industry Companies
 

Industry Analysis

CELG

Industry Average

Valuation CELG Industry Range
Price/Earnings 36.7x
Price/Sales 10.7x
Price/Book 12.6x
Price/Cash Flow 31.6x
TEV/Sales 8.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.